Close

Drug Research

Continuous Bioprocessing Shapes Biopharma Manufacturing

The biopharmaceutical industry happens to be experiencing a massive shift toward continuous bioprocessing. Unlike traditional batch processing, which happens to be involving discrete stages with intermediate holding tanks, consistent bioprocessing operates seamlessly. Cells get grown, and the desired product...

Biotherapeutic Drug Creation – Analytics, Mass Spec Lay Path

In the modern era, biopharmaceutical discovery and development scientists happen to be achieving new levels when it comes to structural insight into therapeutic proteins. By way of utilizing biopharmaceutical analytical technology as well as mass spectrometry, laboratories happen to...

Equitable Access In Pandemics – Biopharma Steps Up Its Worth

The 77th World Health Assembly- WHA goes on to mark the deadline for the conclusion of a pandemic agreement as well as amended International Health Regulations 2005 that look to make the planet much better prepared for the next...

Exothera pledges to fast-track RNA therapies with expansion of world-first continuous-batch RNA manufacturing solution into North America

Belgium-headquartered Exothera, a leading provider of nucleic acids and viral vector development and manufacturing services, has launched its game-changing nucleic acids service offering, powered by the world's first continuous-batch RNA production platform, Ntensifyâ„¢. Developed by Exothera sister company Quantoom...

Drug Wars Continue Despite Registry Patent Listing Crackdown

No company happened to be hit harder by the US Federal Trade Commission’s crackdown when it came to patents listed on the federal registry of approved drugs than Teva Pharmaceutical Industries Ltd., the Israeli drugmaker, and the fact that...

Hovione and GEA Strengthen Partnership to Advance Continuous Tableting Technology

Hovione, the specialist integrated CDMO and leader in spray drying and particle engineering, and GEA, a global leader in process technology for the pharmaceutical industry announced the next stage of their partnership, with new development agreements, the launch of...

ReciBioPharm and GeneVentiv Therapeutics partner to advance first AAV-based gene therapy for haemophilia patients with inhibitors

ReciBioPharm, the advanced and emerging therapies business unit of Recipharm, has announced a collaboration agreement with GeneVentiv Therapeutics, a pre-clinical gene therapy company, to advance development of an Adeno-Associated Virus (AAV)-based universal gene therapy for haemophilia, and the first...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read